The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | MEDI2228 for R/R myeloma
Shaji Kumar, MD, Mayo Clinic, Rochester, MN, reports the efficacy, safety, and pharmacokinetic results of the Phase I, first-in-human trial (NCT03489525) of MEDI2228, an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) in patients with relapsed/refractory (R/R) multiple myeloma. MEDI2228 utilizes pyrrolobenzodiazepine (PBD) to induce cell death of malignant plasma cells. Following dose-escalation and expansion, the trial showed an overall response rate (ORR) of 61.0%, including durable responses and an acceptable safety profile. The adverse events (AE) observed included elevation of liver enzymes, thrombocytopenia, and photophobia, however, efforts are being made to mitigate AEs by adjusting dose schedules. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
